Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.

Timeline

Start

2024-02-26

Primary completion

2025-10-17

Completion

2025-10-17

Outcome

Met primary endpoint

release “RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance” pharvaris.com ↗

release “met the primary and all 11 secondary efficacy endpoints with statistical significance.” pharvaris.com ↗

Drugs

Indications